Clinical Labs of Hawaii provides test updates for educational purposes to physicians, specialists, and the general public.
Please review the Clinical Labs of Hawaii frequently asked questions for answers regarding SARS-CoV-2 (COVID-19) molecular testing.
On May 19, 2020, Clinical Laboratories of Hawaii (CLH) began testing for SARS-CoV-2, the virus that causes COVID-19, using a new high-throughput system, called the Aptima® SARS-CoV-2 Assay conducted on the Hologic Panther instrument.
Please review guidelines from the federal government’s COVID-19 Uninsured Program.
Please review the Clinical Labs of Hawaii frequently asked questions for answers regarding SARS-CoV-2 (COVID-19) serology testing.
Effective April 30, 2020, Clinical Labs of Hawaii began offering serology testing for SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19).
Beginning March 1, 2020, United Healthcare Insurance will require prior authorization/notification for genetic and molecular testing performed in an outpatient setting.
CLH offers the FilmArray Respiratory Panel from BioFire Diagnostics for the detection of 17 respiratory viruses and 3 bacteria from a single specimen. This panel does NOT test for the SARS-CoV-2 virus.
Biotin administration (especially in high doses) may impact common, immunoassay-based, laboratory tests.
CLH/PPPL will be performing Human Papillomavirus (HPV) testing locally on Oahu using the Aptima nucleic acid amplification assay.
Clinical Labs of Hawaii is pleased to offer the Rapid Alere Determine™ HIV-1/2 Ag/Ab Combo qualitative immunoassay for the simultaneous detection of HIV-1 p24 antigen and antibodies to HIV-1 and HIV2.
Test codes for CT-GC testing by Transcription Mediated Amplification (TMA) have been updated.